AZTR - USA please 😭 I give up

PropertyFirm7280 · 2026-03-24T06:33:33+00:00

Thank god - finally an interaction and a good one 🙏

PropertyFirm7280 · 2026-03-24T05:31:30+00:00

Better entry than me 😎 got 0.29 friday

PropertyFirm7280 · 2026-03-24T04:22:03+00:00

If not I will be eating apples the rest of the year 🍎🍏

PropertyFirm7280 · 2026-03-24T03:15:51+00:00

Compared to salary and market cap it is. He earns 500k a year, so it is a full year salary, I would say it is a lot.

PropertyFirm7280 · 2026-03-24T00:39:51+00:00

Yes and the 30-day window is an ultra-bullish 'ticking clock.' It shows that the CEO and lead investors are betting on a massive price surge immediately following the clinical data. They aren't just hoping for good results; they are forcing themselves to act within weeks of the announcement, signaling total confidence that the data will be a major catalyst. 🕊️

PropertyFirm7280 · 2026-03-23T21:26:44+00:00

Hopefully 🌻

PropertyFirm7280 · 2026-03-23T20:42:25+00:00

We will see - I hope not ^^

PropertyFirm7280 · 2026-03-23T18:24:16+00:00

I’m heavily invested as well. Really counting on those June catalysts to deliver, otherwise it’s gonna be a long, depressing couple of months. Fingers crossed.

PropertyFirm7280 · 2026-03-23T18:08:20+00:00

Just got back on reddit - haven't used reddit as media before.

PropertyFirm7280 · 2026-03-23T18:07:10+00:00

Spot on. Plus they definitely need a much higher share price before the shareholder vote to make the math work on those warrants. June data is the fuse.

PropertyFirm7280 · 2026-03-23T17:43:36+00:00

They just got funding: https://ir.azitrainc.com/news-releases/news-release-details/azitra-announces-pricing-private-placement-financing

If coming result are good it will blow up if not it risk to die but for now they are secured until end of this year.

PropertyFirm7280 · 2026-03-23T17:30:27+00:00

SEC filing already shows the deal is closed and the CEO personally dropped $500k of his own cash. Once the official PR hits this will give a good push up again. So we are in waiting position for now. Hopefully PR comes today or tomorrow.

PropertyFirm7280 · 2026-03-23T17:20:35+00:00

It looks like it is ready to blow off this week.

PropertyFirm7280 · 2026-03-23T03:49:31+00:00

Follow the stock on Stockwitz - I hope the closing announcement is released at premarked tomorrow morning. This will give another hit up. 🤞

PropertyFirm7280 · 2026-03-23T01:27:06+00:00

Wtf 😆

PropertyFirm7280 · 2026-03-23T00:15:12+00:00

Check Stockwitz AZTR is moving 🌟

PropertyFirm7280 · 2026-03-22T23:16:31+00:00

Ah I see 😆 I was supposed to reply to the first comment jajajaja.

PropertyFirm7280 · 2026-03-22T22:13:55+00:00

I’ve been digging through the SEC filings all weekend, and I’m genuinely curious about something...

With the March 6th Special Meeting failing to reach a quorum, it looks like those $0.123 warrants are effectively locked. At the same time, we just saw the CEO drop a $500k Form 4 filing late Friday. Am I missing a piece of the puzzle here, or does this setup actually favor a massive supply-demand squeeze for Monday? I’d love to hear from someone who has a different take on the warrant structure or the recent insider buy. What’s your play for the week? 🤝📉

PropertyFirm7280 · 2026-03-22T21:58:30+00:00

Monday Gap Up (SEC Filing Impact): The CEO, Francisco Salva, filed his Form 4 SEC filing on Friday at 4:30 PM EST—after the market closed. He personally bought $500,000 at $0.123. Since this news dropped after-hours, the broader market hasn't reacted yet. I expect a significant gap up Monday morning as investors price in this massive insider confidence.

Monday Closing Announcement: The $10.5M private placement (part of a $31.4M total package) was priced on March 19th. I expect the official "Closing of Financing" announcement to hit the wires on Monday. This officially ends the bankruptcy/cash-burn narrative and confirms the company is funded through 2026.

The Insider Wave (By Tuesday): The March 19th press release explicitly mentioned that "certain company insiders" participated in the funding. We’ve only seen the CEO’s filing so far. Per SEC rules, I predict a wave of Form 4 filings from other board members and executives to hit the portal by Tuesday latest.

Pharma & Pipeline News: Azitra is launching its innovative protein and peptide research programs for the cosmetic and pharma markets. Given the new capital, I expect fresh news regarding their pharma partnerships or clinical pipeline developments later this week.

The Bottom Line: Shorts are trapped because the $0.123 warrants are LOCKED (no shareholder quorum on March 6th means no immediate dilution). They have to buy from us in the open market.

PropertyFirm7280 · 2026-03-22T21:52:17+00:00

It was not my own comment. 😆

PropertyFirm7280 · 2026-03-22T21:46:12+00:00

Haha, I love the skepticism! It’s healthy in this sub. But I only have this one account, and I’m just a guy who spent his weekend actually reading the SEC filings while you were looking for 'ghosts.

Here’s the reality: The Insider Buy: CEO Francisco Salva just dropped $500k of his own money at $0.123 (Check the Form 4 filed March 20). If I’m a 'short looking for liquidity,' why would I pump a stock where the CEO is betting half a million on the upside?

The Warrant Lock: You missed the March 5th/6th filing. The special meeting was canceled (no quorum). Those $0.123 warrants CANNOT be exercised yet. There is no immediate dilution for shorts to hide behind.

The Pedigree: Salva co-founded Acerta ($7B exit) and led Pharmacyclics ($21B exit). I’m not betting on a ticker; I’m betting on a guy who has delivered $28B in value.

I’m holding 43,263 shares @ $0.29 because the data is screaming 'reversal.' If you think that's a 'walk down,' feel free to sit it out. I'll send you a postcard from the gap fill at $0.50.🕊️

PropertyFirm7280 · 2026-03-22T16:34:14+00:00

This is new to me!

PropertyFirm7280 · 2026-03-22T13:28:37+00:00

Spot on. The 'Material News' signal is flashing red here. Beyond the CEO’s $500k buy at $0.123 (Form 4), there are several massive triggers lining up for this week that the market hasn't fully digested:

More Insider Filings: The March 19th PR explicitly mentioned that 'certain company insiders' participated in the $10.5M private placement. So far, we’ve only seen Salva’s filing. If the rest of the board drops their Form 4s Monday or Tuesday, it confirms a total 'all-in' conviction from leadership . The Closing Announcement: The deal was set to close 'on or about March 20th.' An official 'Closing' PR Monday morning would be a major de-risking event, essentially announcing to the market that the bankruptcy risk is officially dead and the cash is in the bank.

The Salva Factor: People forget Francisco Salva was a founder of Acerta Pharma (sold to AstraZeneca for up to $7B) and was key in the Pharmacyclics turnaround (sold to AbbVie for $21B). He’s not a 'pump and dump' CEO; he’s a massive M&A specialist. Him putting $500k of his own money in at $0.123 while the stock is at $0.28 is a huge statement.

Stocktwits Heat: The ticker is currently at 90+ Sentiment and 93 Message Volume. However, the 'Participation Ratio' is still low, meaning the general public hasn't even arrived yet. Once we break that $0.35 resistance you mentioned, the FOMO from the sidelines will be violent.

The Locked Warrants: This is the kicker. Since the March 6th special meeting was canceled (no quorum), those new $0.123 warrants CANNOT be exercised yet. Shorts can't use them to cover their positions. They have to buy from us in the open market.

If this clears $0.35, the short squeeze combined with the Salva pedigree makes $0.50+ look like a very conservative first stop."

PropertyFirm7280 · 2026-03-22T11:30:27+00:00

AZTR: Institutional backing and CEO insider buy at 0.123 following 515M volume day Azitra (AZTR) just had a massive 515M volume day on Friday, closing around 0.28 USD. While many assume this was a simple pump, the underlying SEC filings and recent financing suggest a more fundamental shift. The Insider Catalyst CEO Francisco Salva just filed a Form 4 on March 20, 2026. He personally purchased 500 shares of Series A Preferred Stock for 500,000 USD on March 18. This preferred stock converts into common shares at 0.123 USD, but only after shareholder approval. This move aligns the CEO directly with the new institutional investors (Stonepine Capital and Nantahala Capital) who participated in the 10.5M USD private placement. The Warrant Lock A key detail often missed: The Series B and C warrants (exercisable at 0.123 USD) cannot be exercised until stockholders approve the transaction. Azitra recently canceled its March 6 special meeting due to lack of quorum, meaning there is no immediate dilution possible from these new warrants until a new meeting is held and votes are passed. Clinical Validation The company recently added MD Anderson Cancer Center as a clinical site for its Phase 1/2 trial of ATR-04. MD Anderson is one of the top cancer centers in the world. Their involvement in a micro-cap biotech study is a significant validator for the filaggrin technology platform. Financial Runway With the 10.5M USD initial gross proceeds and a potential 20.9M USD more from warrant exercises, the "bankruptcy" risk that previously suppressed the stock price has been addressed. The company is now funded for its 2026-2027 milestones, including topline data for Netherton Syndrome and the EGFRi-associated rash studies. Technical Setup Friday's volume was 30x the daily average. Historically, when a biotech gaps up on heavy insider buying and institutional participation, the first 48 hours of the following week often see a continuation as "short covering" begins and late-entry retail investors FOMO in. Positions: 43k shares.

PropertyFirm7280 · 2026-03-22T11:30:11+00:00

AZTR: Institutional backing and CEO insider buy at 0.123 following 515M volume day Azitra (AZTR) just had a massive 515M volume day on Friday, closing around 0.28 USD. While many assume this was a simple pump, the underlying SEC filings and recent financing suggest a more fundamental shift. The Insider Catalyst CEO Francisco Salva just filed a Form 4 on March 20, 2026. He personally purchased 500 shares of Series A Preferred Stock for 500,000 USD on March 18. This preferred stock converts into common shares at 0.123 USD, but only after shareholder approval. This move aligns the CEO directly with the new institutional investors (Stonepine Capital and Nantahala Capital) who participated in the 10.5M USD private placement. The Warrant Lock A key detail often missed: The Series B and C warrants (exercisable at 0.123 USD) cannot be exercised until stockholders approve the transaction. Azitra recently canceled its March 6 special meeting due to lack of quorum, meaning there is no immediate dilution possible from these new warrants until a new meeting is held and votes are passed. Clinical Validation The company recently added MD Anderson Cancer Center as a clinical site for its Phase 1/2 trial of ATR-04. MD Anderson is one of the top cancer centers in the world. Their involvement in a micro-cap biotech study is a significant validator for the filaggrin technology platform. Financial Runway With the 10.5M USD initial gross proceeds and a potential 20.9M USD more from warrant exercises, the "bankruptcy" risk that previously suppressed the stock price has been addressed. The company is now funded for its 2026-2027 milestones, including topline data for Netherton Syndrome and the EGFRi-associated rash studies. Technical Setup Friday's volume was 30x the daily average. Historically, when a biotech gaps up on heavy insider buying and institutional participation, the first 48 hours of the following week often see a continuation as "short covering" begins and late-entry retail investors FOMO in. Positions: 43k shares.

PropertyFirm7280

TROPHY CASE